Immunic, Inc. (NASDAQ:IMUX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given an average recommendation of “Buy” by the six analysts that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $11.20.

Several research analysts have recently issued reports on IMUX shares. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler reissued an “overweight” rating and issued a $28.00 target price on shares of Immunic in a report on Tuesday, July 16th. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a report on Monday, September 9th.

Immunic Stock Up 2.0 %

Immunic stock opened at $1.52 on Monday. Immunic has a twelve month low of $0.95 and a twelve month high of $1.92. The company has a market capitalization of $136.92 million, a P/E ratio of -0.83 and a beta of 1.82. The stock’s 50 day moving average is $1.40 and its 200 day moving average is $1.31.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same period in the prior year, the company earned ($0.54) EPS. As a group, equities analysts expect that Immunic will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the company. BVF Inc. IL purchased a new stake in Immunic during the first quarter valued at $11,752,000. Janus Henderson Group PLC bought a new stake in shares of Immunic during the 1st quarter valued at about $9,266,000. Vanguard Group Inc. increased its position in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. Gratus Capital LLC lifted its stake in shares of Immunic by 15.1% in the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after purchasing an additional 254,999 shares during the period. Finally, Ikarian Capital LLC boosted its holdings in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after buying an additional 1,162,378 shares during the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.